Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.87 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.49 |
| ▸ | CECR2 | Q9BXF3 | 3/20 | 0.47 |
| ▸ | TAF1 | P21675 | 4/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748951 | 0.93 | BRD4 (1.00) | BRD4BRD9CECR2TAF1TRIM24 | |
| SCHEMBL17748885 | 0.87 | BRD4 (0.66) | BRD4BRD9CECR2TAF1TRIM24 | |
| SCHEMBL17748909 | 0.71 | CECR2 (0.65) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL17748905 | 0.70 | BRD4 (0.61) | BRD4BRD9CECR2TAF1TRIM24 | |
| SCHEMBL15074680 | 0.70 | KDM4E (0.58) | BRD4 | |
| SCHEMBL1734404 | 0.70 | ESR2 (0.55) | BRD4CREBBP | |
| SCHEMBL17748897 | 0.70 | BRD9 (0.69) | BRD4BRD9CECR2TAF1TRIM24 | |
| SCHEMBL398708 | 0.69 | BRD4 (0.59) | BRD4CREBBP | |
| SCHEMBL29984623 | 0.69 | BRD4 (0.59) | BRD4CREBBP | |
| SCHEMBL17795396 | 0.69 | BRD4 (0.45) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | claimed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | claimed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | claimed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | claimed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342067-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD9 12/4885CECR2 246/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD9 12/4885CECR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.